Is fulvestrant, alone or in combination with the aromatase inhibitor anastrozole, superior to anastrozole alone as neoadjuvant endocrine therapy (NET) in postmenopausal women with estrogen receptor (ER)–rich/ERBB2-negative breast cancer, in terms of endocrine-sensitive disease rate (ESDR)? This evidence concerns the gene ERBB2 and breast cancer.